Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Dexamethasone 124Lenalidomide 72daratumumab 71Bortezomib 58pomalidomide 47carfilzomib 42Cyclophosphamide 39Calcium Dobesilate 36Specimen Handling 31Biopsy 29Magnetic Resonance Spectroscopy 26belantamab mafodotin 22isatuximab 21fludarabine 20iberdomide 18talquetamab 17Melphalan 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 14fludarabine phosphate 13elotuzumab 12selinexor 10tocilizumab 9X-Rays 8Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Emapalumab × 90 days × Clear all
NCT07567014 2026-05-06

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

NYU Langone Health

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡